Display options
Cite
Longuespée R, Couture F, Levesque C, et al. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol. 2014;doi: 10.1016/j.tranon.2014.04.008.
Longuespée, R., Couture, F., Levesque, C., Kwiatkowska, A., Desjardins, R., Gagnon, S., Vergara, D., Maffia, M., Fournier, I., Salzet, M., & Day, R. (2014). Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Translational oncology, . https://doi.org/10.1016/j.tranon.2014.04.008
Longuespée, Rémi, et al. "Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target." Translational oncology vol. (2014). doi: https://doi.org/10.1016/j.tranon.2014.04.008
Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol. 2014 May 09; doi: 10.1016/j.tranon.2014.04.008. Epub 2014 May 09. PMID: 24818756; PMCID: PMC4145398.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2014 May 09; doi: 10.1016/j.tranon.2014.04.008. Epub 2014 May 09.

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Translational oncology

Rémi Longuespée, Frédéric Couture, Christine Levesque, Anna Kwiatkowska, Roxane Desjardins, Sandra Gagnon, Daniele Vergara, Michelle Maffia, Isabelle Fournier, Michel Salzet, Robert Day

Affiliations

  1. MALDI Imaging Team, Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, Université Nord de France, Cité Scientifique, Université de Lille 1, Villeneuve D'Ascq, France; Faculté de Médecine et des Sciences de la Santé, Institut de Pharmacologie de Sherbrooke et Département de chirurgie et service d'urologie, Université de Sherbrooke, Sherbrooke, Canada.
  2. Faculté de Médecine et des Sciences de la Santé, Institut de Pharmacologie de Sherbrooke et Département de chirurgie et service d'urologie, Université de Sherbrooke, Sherbrooke, Canada.
  3. MALDI Imaging Team, Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, Université Nord de France, Cité Scientifique, Université de Lille 1, Villeneuve D'Ascq, France; Laboratory of Clinical Proteomic, "Giovanni Paolo II" Hospital, ASL-Lecce, Italy.
  4. Laboratory of Clinical Proteomic, "Giovanni Paolo II" Hospital, ASL-Lecce, Italy.
  5. MALDI Imaging Team, Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, Université Nord de France, Cité Scientifique, Université de Lille 1, Villeneuve D'Ascq, France.
  6. MALDI Imaging Team, Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, Université Nord de France, Cité Scientifique, Université de Lille 1, Villeneuve D'Ascq, France. Electronic address: [email protected].
  7. Faculté de Médecine et des Sciences de la Santé, Institut de Pharmacologie de Sherbrooke et Département de chirurgie et service d'urologie, Université de Sherbrooke, Sherbrooke, Canada. Electronic address: [email protected].

PMID: 24818756 PMCID: PMC4145398 DOI: 10.1016/j.tranon.2014.04.008

Abstract

Proprotein convertases are a family of kexin-like serine proteases that process proteins at single and multiple basic residues. Among the predicted and identified PC substrates, an increasing number of proteins having functions in cancer progression indicate that PCs may be potential targets for antineoplastic drugs. In support of this notion, we identified PACE4 as a vital PC involved in prostate cancer proliferation and progression, contrasting with the other co-expressed PCs. The aim of the present study was to test the importance of PCs in ovarian cancer cell proliferation and tumor progression. Based on tissue-expression profiles, furin, PACE4, PC5/6 and PC7 all displayed increased expression in primary tumor, ascites cells and metastases. These PCs were also expressed in variable levels in three model ovarian cell lines tested, namely SKOV3, CAOV3 and OVCAR3 cells. Since SKOV3 cells closely represented the PC expression profile of ovarian cancer cells, we chose them to test the effects of PC silencing using stable gene-silencing shRNA strategy to generate knockdown SKOV3 cells for each expressed PC. In vitro and in vivo assays confirmed the role of PACE4 in the sustainment of SKOV3 cell proliferation, which was not observed with the other three PCs. We also tested PACE4 peptide inhibitors on all three cell lines and observed consequent reduced cell proliferation which was correlated with PACE4 expression. Overall, these data support a role of PACE4 in promoting cell proliferation in ovarian cancer and provides further evidence for PACE4 as a potential therapeutic target.

Copyright © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. All rights reserved.

Keywords: PACE4; SKOV3 cells; proprotein convertases; xenografts

References

  1. Cancer Res. 2005 Aug 15;65(16):7310-9 - PubMed
  2. Int J Cancer. 1997 Jun 11;71(6):966-71 - PubMed
  3. Proteomics Clin Appl. 2013 Jun;7(5-6):337-54 - PubMed
  4. Neoplasia. 2012 Nov;14(11):1032-42 - PubMed
  5. J Immunol Methods. 1991 Sep 13;142(2):257-65 - PubMed
  6. Med Sci Monit. 2010 Sep;16(9):BR293-9 - PubMed
  7. J Med Chem. 2014 Jan 9;57(1):98-109 - PubMed
  8. Diagn Pathol. 2007 Feb 27;2:8 - PubMed
  9. Trends Pharmacol Sci. 2005 Jun;26(6):294-301 - PubMed
  10. Transl Oncol. 2011 Jun;4(3):157-72 - PubMed
  11. Biochem J. 1996 Mar 1;314 ( Pt 2):521-32 - PubMed
  12. Nat Biotechnol. 2010 Mar;28(3):281-8 - PubMed
  13. Acta Pharmacol Sin. 2012 Jun;33(6):817-22 - PubMed
  14. Neuropathol Appl Neurobiol. 2012 Apr;38(2):201-12 - PubMed
  15. Mol Carcinog. 2001 Aug;31(4):224-32 - PubMed
  16. Biomol Concepts. 2011 Oct 1;2(5):421-438 - PubMed
  17. Mol Cell Endocrinol. 2003 Apr 28;202(1-2):89-96 - PubMed
  18. Ned Tijdschr Geneeskd. 1978 Jan 21;122(3):65-8 - PubMed
  19. PLoS One. 2010 Oct 27;5(10):e13665 - PubMed
  20. J Low Genit Tract Dis. 2011 Oct;15(4):280-6 - PubMed
  21. Cell Oncol. 2007;29(4):289-99 - PubMed
  22. Am J Pathol. 2011 Jul;179(1):400-10 - PubMed
  23. J Exp Clin Cancer Res. 2004 Mar;23(1):135-41 - PubMed
  24. Histochem Cell Biol. 2012 Jul;138(1):141-54 - PubMed
  25. Reproduction. 2011 Mar;141(3):343-55 - PubMed
  26. Nat Rev Drug Discov. 2012 May;11(5):367-83 - PubMed
  27. Urology. 1999 Apr;53(4):707-13 - PubMed
  28. Am J Surg Pathol. 2010 Mar;34(3):433-43 - PubMed
  29. Mol Cancer Res. 2003 Jun;1(8):569-76 - PubMed
  30. Cancer Res. 2008 Apr 1;68(7):2329-39 - PubMed
  31. BMC Cancer. 2009 Jan 12;9:11 - PubMed
  32. J Med Chem. 2012 Dec 13;55(23):10501-11 - PubMed
  33. Med Sci Monit. 2010 Aug;16(8):BR233-45 - PubMed
  34. Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32 - PubMed
  35. Am J Pathol. 2002 Jun;160(6):1921-35 - PubMed
  36. Eur J Cancer. 2013 Apr;49(6):1374-403 - PubMed
  37. Curr Pharm Des. 2002;8(7):549-62 - PubMed
  38. Methods Mol Biol. 2014;1103:67-82 - PubMed
  39. Carcinogenesis. 2002 Apr;23(4):565-72 - PubMed
  40. Anal Chem. 2013 Feb 19;85(4):2117-26 - PubMed
  41. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  42. J Cell Biol. 1993 Feb;120(3):577-85 - PubMed

Publication Types